Protalix, Chiesi fire up accelerated approval pitch for Fabry disease treatment
When Protalix BioTherapeutics reported its 2018 results this March, it spent much of its time talking up the potential of nabbing an accelerated approval for its Fabry disease treatment pegunigalsidase alfa.
Weeks later, the Israeli biotech — which has an unappetizing penny stock valuation $PLX — and partner Chiesi are going for it, optimistic after months of discussion with the FDA. The BLA filing is scheduled for Q1 2020.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.